Hidradenocarcinoma: A Rare Skin Disease

Year : 2024 | Volume : 02 | Issue : 01 | Page : 1-12
    By

    Aanchal Bhatia,

  • Muskan Tiwari,

  • Gaganpreet Kaur,

  1. Student, Department of Agricultural Biotechnology, Punjab Agricultural University (PAU), Ludhiana, Punjab, India
  2. Student, Department of Agricultural Biotechnology, Punjab Agricultural University (PAU), Ludhiana, Punjab, India
  3. Assistant Professor, Department of Agricultural Biotechnology, Punjab Agricultural University (PAU), Ludhiana, Punjab, India

Abstract

Hidradenocarcinoma (HAC) also known as ‘‘sweat gland tumor” is an aggressive, uncommon, highly malignant, adnexal tumor derived from the intradermal duct of eccrine sweat glands. It is said to be aggressive as it has a high risk of local recurrence (50%–75%) and a high potential to metastasize to nearby lymph nodes or to other distant sites. Hidradenocarcinoma has other recognized variants which are known by different names such as Malignant Acrospiroma, Nodular Hidradenocarcinoma, Clear cell Hidradenocarcinoma, Malignant Nodular Hidradenoma, Malignant Clear Cell Hidradenoma, clear cell eccrine carcinoma or simply sweat gland tumor. However, the term Hidradenocarcinoma (HAC) is the recommended name. This malignant tumor arises from the eccrine glands which are located in sun-exposed locations. These malignancies exhibit a high reactivity to eccrine enzymatic stains and their morphologic features are seen under the electron microscope, so that’s why they are known to originate in the sweat glands. The occurrence rate is about 0.001% of all malignant tumors and Hidradenocarcinoma accounts for approximately 6% of malignant eccrine tumors, which in turn are found in 1:13,000 skin biopsies and <0.001% of all skin cancers. They usually appear de novo on healthy skin, or sometimes malignant transformation from their benign form. In 1865, French pathologist Victor Andre Cornil described the first case of sweat gland cancer. Hidradenocarcinoma (HAC) was first reported in 1948 in Brazil and was first described as a clear cell eccrine carcinoma by Keasby and Hadley in 1954. When Keasby first described this tumor in 1954 he found only 3 cases of hidradenocarcinoma among 235 sweat gland tumors.

Keywords: Tumor, carcinoma, hidradenocarcinoma, hidradenoma, malignant

[This article belongs to International Journal of Cell Biology and Cellular Functions ]

How to cite this article:
Aanchal Bhatia, Muskan Tiwari, Gaganpreet Kaur. Hidradenocarcinoma: A Rare Skin Disease. International Journal of Cell Biology and Cellular Functions. 2024; 02(01):1-12.
How to cite this URL:
Aanchal Bhatia, Muskan Tiwari, Gaganpreet Kaur. Hidradenocarcinoma: A Rare Skin Disease. International Journal of Cell Biology and Cellular Functions. 2024; 02(01):1-12. Available from: https://journals.stmjournals.com/ijcbcf/article=2024/view=145718


Browse Figures

References

1. Kane B, Adler E, Bhandari T, Rose M, DiGuglielmo N, Sun X. Malignant hidradenocarcinoma in the lower extremity: A case report of a rare tumor. J Foot Ankle Surg. 2018;57:618–21. DOI: 10.1053/j.jfas.2017.10.024, PubMed: 29472169.
2. Mackenzie DH. A clear-cell hidradenocarcinoma with metastases. Cancer. 1957;10:1021–3. DOI: 10.1002/1097-0142(195709/10)10:53.0.co;2-q, PubMed: 13472651.
3. Ryu WC, Lee YH, Koh IC, Sohn JS, Jang SM. Hidradenocarcinoma of the dorsum of the hand. Chin Med J. 2017;130:1755–6. DOI: 10.4103/0366-6999.209899, PubMed: 28685735.
4. Singh R, Brewer J, Bernstein ZP, Higgs D. No sweat, a rare case of hidradenocarcinoma. Am Surg. 2012;78:92–3. DOI: 10.1177/000313481207800218, PubMed: 22369809.
5. Lim J, Park SY, Lew H, Cho K. Hidradenocarcinoma on the orbit. Nerve. 2018;4:16–9. DOI: 10.21129/nerve.2018.4.1.16.
6. Singh G, Narasimha A, Kumar H, Datti N. Clear cell hidradenocarcinoma of the eyelid: A case report with a review of the literature. Int Ophthalmol. 2013;33:171–5. DOI: 10.1007/s10792-012-9645-y, PubMed: 23053773.
7. Farooq U, Choudhary S, Russo J, Vincek V, Elgart G. Clear cell hidradenocarcinoma with helpful immunohistochemistry: A case report. Int J Dermatol. 2013;52:1380–2. DOI: 10.1111/j.1365-4632.2011.05433.x, PubMed: 22998159.
8. Nazarian RM, Kapur P, Rakheja D, Piris A, Duncan LM, Mihm Jr MC, Hoang MP. Atypical and malignant hidradenomas: A histological and immunohistochemical study. Mod Pathol. 2009;22:600–10. DOI: 10.1038/modpathol.2009.18, PubMed: 19252473.
9. Ko CJ, Cochran AJ, Eng W, Binder SW. Hidradenocarcinoma: A histological and immunohistochemical study. J Cutan Pathol. 2006;33:726–30. DOI: 10.1111/j.1600-0560.2006.00536.x, PubMed: 17083691.
10. Gupta E, Guthrie KJ, Krishna M, Asmann Y, Parker AS, Joseph RW. Whole exome sequencing of a patient with metastatic hidradenocarcinoma and review of the literature. Rare Tumors. 2015;7:29–33. DOI: 10.4081/rt.2015.5719.
11. Latorre A, Alghothani L, Lambert D, Jatana KR, Peters S, Foster J, Hill R. Mucin-producing malignant tumor of lower eyelid presenting in a 14-year-old patient. J Clin Aesthet Dermatol. 2012;5:44–7. PubMed: 22708009.
12. Nongkynrih A, Kamboj K, Dhull AK, Kaushal V. Miraculous response to radiotherapy in a rare case of malignant nodular hidradenoma nose. J Cancer Prev Curr Res. 2018;9:97–9.
13. Wiedemeyer K, Brenn T. Malignant skin adnexal tumors: Pathology and genetics. In: Boffetta P, Hainaut P, editors. Encyclopedia of Cancer. 3rd ed. Academic Press; 2019. p. 389–401. DOI: 10.1016/B978-0-12-801238-3.65096-1.
14. Kersting DW. Clear cell hidradenoma and hidradenocarcinoma. Arch Dermatol. 1963;87:323–33. DOI: 10.1001/archderm.1963.01590150039007, PubMed: 14032110.
15. Patel N, Kramer A, Sun X. A case of clear cell hidradenoma found during abdominal cyst excision. Cureus. 2022;14. DOI: 10.7759/cureus.22957, PubMed: 35411271.
16. Ham T, Cheon SJ, Roh MS, Ha DH. Ultrasonography of malignant clear cell hidradenoma: A case report. Taehan Yongsang Uihakhoe Chi. 2020;81:448–52. DOI: 10.3348/jksr.2020.81.2.448, PubMed: 36237377.
17. Ahn CS, Sangüeza OP. Malignant sweat gland tumors. Hematol Oncol Clin North Am. 2019;33:53–71. DOI: 10.1016/j.hoc.2018.09.002, PubMed: 30497677.
18. Baklacı D, Kum RO, Yilmaz Y, Özcan M, Ünal A. An unusual tumor of the lower lip: Benign nodular hidradenoma. Entomologist. 2017.
19. Kazakov DV, Ivan D, Kutzner H, Spagnolo DV, Grossmann P, Vanecek T, Sima R, Kacerovska D, Shelekhova KV, Denisjuk N, et al. Cutaneous hidradenocarcinoma: A clinicopathological, immunohistochemical, and molecular biologic study of 14 cases, including Her2/neu gene expression/amplification, TP53 gene mutation analysis, and t(11;19) translocation. Am J Dermatopathol. 2009;31:236–47. DOI: 10.1097/DAD.0b013e3181984f10, PubMed: 19384064.
20. Driscoll JJ, Gauerke S, Monahan BC. Mechanistic and treatment implications of ΔNp63 expression in a rare case of metastatic hidradenocarcinoma. Case Rep Oncol. 2009;2:44–52. DOI: 10.1159/000205351, PubMed: 20740144.
21. An JK, Woo JJ, Hong YO. Malignant sweat gland tumor of breast arising in pre-existing benign tumor: A case report. World J Clin Cases. 2019;7(19):3033–8. DOI: 10.12998/wjcc.v7.i19.3033, PubMed: 31624751.
22. Martins D, Pereira F, Azevedo R, Julião I. Eccrine hidradenocarcinoma of the scalp. Cureus. 2022;14(4). DOI: 10.7759/cureus.23023, PubMed: 35419234.
23. Mir Khan B, Mansha MA, Ali N, Abbasi ANN, Ahmed SM, Qureshi BM. Hidradenocarcinoma: Five years of local and systemic control of a rare sweat gland neoplasm with nodal metastasis. Cureus. 2018;10(8). DOI: 10.7759/cureus.2884, PubMed: 30155386.
24. Sanders DSA, Carr RA. The use of immunohistochemistry in the differential diagnosis of common epithelial tumours of the skin. Curr Diagn Pathol. 2007;13(3):237–51. DOI: 10.1016/j.cdip.2007.
05.012.
25. Soni A, Bansal N, Kaushal V, Chauhan AK. Current management approach to hidradenocarcinoma: A comprehensive review of the literature. Ecancermedicalscience. 2015;9:517. DOI: 10.3332/
ecancer.2015.517, PubMed: 25815059.
26. Cleaveland P, Srivastava P, Oliveira P, Parnham A, Elliott T, Sangar V. A rare presentation of hidradenocarcinoma within the penis. Urol Case Rep. 2019;22:57–9. DOI: 10.1016/j.eucr.2018.10.016, PubMed: 30510902.
27. Ohta M, Hiramoto M, Fujii M, Togo T. Nodular hidradenocarcinoma on the scalp of a young woman: Case report and review of literature. Dermatol Surg. 2004;30(8):1265–8. DOI: 10.1111/j.1524-4725.2004.30390.x, PubMed: 15355375.
28. Elbenaye J, Moumine M, Sinaa M, Elhaouri M. Fatal hidradenocarcinoma of the scalp: A case report. Eur Ann Otorhinolaryngol Head Neck Dis. 2017;134(4):291–2. DOI: 10.1016/j.anorl.2017.03.008, PubMed: 28410954.
29. Holden B, Colome-Grimmer M, Savage C, Stierman K, Pou AM. Malignant eccrine acrospiroma with metastasis to the parotid. Ear Nose Throat J. 2002;81(5):352–5. DOI: 10.1177/014556130208100515, PubMed: 12025008.
30. Son ET, Choi HJ, Lee HJ. Case report: Clear cell hidradenocarcinoma of the nail bed. Int Wound J. 2016;13(6):1067–9. DOI: 10.1111/iwj.12482, PubMed: 26416223.
31. Dillon C, Sevensma K, Morgan W. Treatment of hidradenocarcinoma of the scalp with wide local excision: Case report of a rare and malignant tumor. Ann Clin Case Rep. 2019;4:1746.
32. Stanciu A, Florica CE, Zota A, Tebeica T, Leventer M, Bobirca F. Surgical outcomes of more than 1300 cases of Mohs micrographic surgeries from a private Mohs clinic in Romania. Chirurgia. 2020;115(1):69–79. DOI: 10.21614/chirurgia.115.1.69, PubMed: 32155401.
33. Bedada AG, Georges A, Eshetu AB. Perianal malignant nodular hidradenoma in HIV infected pregnant patient. S Afr J Surg. 2018;56(2):64–6. DOI: 10.17159/2078-5151/2018/v56n2a2516.

Regular Issue Subscription Case Study
Volume 02
Issue 01
Received 15/02/2024
Accepted 29/02/2024
Published 09/05/2024
Total Visits: 225


My IP

PlumX Metrics